How inherited cancer risks can be used for effective personalized therapy
Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...
MedPage Today3d
Survival Benefit in Metastatic CRPC Study Spurs Questions on Patient Selection
In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake ...
News-Medical.Net on MSN1d
Study uncovers protective mechanism of BRCA2 in cancer treatment
Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...
Lantern Pharma outlines 2025 clinical milestones and key updates on oncology trials
Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones ...
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
The American Journal of Managed Care7d
Examination of FOXP1 in SCLC Yields Potential Strategy Against Chemoresistance
Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.
Advances in diagnostic pathology pave way for personalised cancer therapy in women
Evolution in women's cancer diagnostics: from histopathology to molecular testing, personalized treatment for breast, ovarian ...
Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...